Literature DB >> 761445

Kinetics of cis-dichlorodiammineplatinum.

P E Gormley, J M Bull, A F LeRoy, R Cysyk.   

Abstract

The cancer chemotherapeutic cis-dichlorodiammineplatinum (cis-DDP) was administered to 8 patients (1-hr intravenous infusion) at a dose of 70 mg/m2. Plasma and urine concentrations of platinum were determined by flameless atomic absorption spectrometry. Measured plasma platinum concentrations revealed a biphasic clearance of platinum with half-life values of 23 min and 67 hr. Platinum values obtained 3 wk after the infusion indicated that a third excretory phase might be present. Urinary measurements showed 17 +/- 2.7% of the administered dose excreted in the first 4 hr and 23 +/- 3.9% excreted in the first 24 hr. Renal excretion appears to be predominantly by glomerular filtration. Non-protein-bound plasma platinum values were calculated and the non-protein-bound platinum was found to be rapidly and biphasically cleared from the plasma with half-life values of 8 to 10 min and 40 to 45 min.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 761445     DOI: 10.1002/cpt1979253351

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  55 in total

1.  Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients.

Authors:  Toru Ishibashi; Yoshitaka Yano; Takayoshi Oguma
Journal:  Br J Clin Pharmacol       Date:  2003-08       Impact factor: 4.335

Review 2.  Effect of haemodialysis on the pharmacokinetics of antineoplastic drugs.

Authors:  Masatoshi Tomita; Yoichi Aoki; Kenichi Tanaka
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

Review 3.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

4.  Nonlinear renal clearance of ultrafilterable platinum in patients treated with cis-dichlorodiammineplatinum (II).

Authors:  P A Reece; I Stafford; J Russell; P G Gill
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

5.  Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat.

Authors:  F F Farris; F G King; R L Dedrick; C L Litterst
Journal:  J Pharmacokinet Biopharm       Date:  1985-02

6.  In vitro plasma binding of some second generation antitumor platinum complexes.

Authors:  R Momburg; M Bourdeaux; M Sarrazin; F Roux; C Briand
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jan-Mar       Impact factor: 2.441

7.  Effects of storage on the binding of carboplatin to plasma proteins.

Authors:  K Erkmen; M J Egorin; L M Reyno; R Morgan; J H Doroshow
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

8.  Permeability change and brain tissue damage after intracarotid administration of cisplatin studied by double-tracer autoradiography in rats.

Authors:  S Sugimoto; Y L Yamamoto; S Nagahiro; M Diksic
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

9.  Cisplatin pharmacokinetics in a child receiving peritoneal dialysis.

Authors:  Judit Sebestyen; Uttam Garg; Karen B Lewing; Bradley A Warady; Susan Abdel-Rahman; Douglas L Blowey
Journal:  Pediatr Nephrol       Date:  2010-01-19       Impact factor: 3.714

10.  Pharmacokinetics and plasma protein binding of two platinum cytostatics CHIP and CBDCA in rats.

Authors:  A Láznícková; M Láznícek; J Kvĕtina; J Drobník
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.